Loading...
•
Sep 30, 2020
Co-Diagnostics Q3 2020 Earnings Report
Announced Q3 2020 financial results and provided updates on company developments.
Key Takeaways
Co-Diagnostics announced financial results for the third quarter ended September 30, 2020, reporting widespread uptake of their COVID-19 test domestically and abroad. The company also received CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests.
Co-Diagnostics continues to see widespread uptake of COVID-19 test domestically and abroad.
Customer and distributor bases are laying the foundation for a strong future.
Development projects have helped position Co-Diagnostics as a key player in the battle against the coronavirus pandemic.
Received two important CE markings that will allow ABC and COVID-19 2-gene tests to be sold as in vitro diagnostics in areas that accept CE markings as valid regulatory approval.
Forward Guidance
The company expects continued growth and expansion in the near future, driven by its technology platform and expanding menu of critical diagnostic tools.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...